Serous cystadenocarcinoma

Last updated
Serous cystadenocarcinoma
Incidence of ovarian cancers by histopathology.png
Ovarian cancers in women aged 20+, with area representing relative incidence and color representing 5-year relative survival rate. [1] Serous cystadenocarcinoma is labeled at bottom left.
Specialty Oncology   OOjs UI icon edit-ltr-progressive.svg

Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma grouping.

Most commonly, the primary site of serous cystadenocarcinoma is the ovary. Rare occurrence in the pancreas has been reported, although this is not typical, with the majority of microcystic pancreatic masses representing alternate disease processes such as the more benign serous cystadenoma. [1] [2] [3]

Related Research Articles

Pancreatic cancer Endocrine gland cancer located in the pancreas

Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass. These cancerous cells have the ability to invade other parts of the body. A number of types of pancreatic cancer are known.

Ovarian cancer Cancer originating in or on the ovary

Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body. When this process begins, there may be no or only vague symptoms. Symptoms become more noticeable as the cancer progresses. These symptoms may include bloating, pelvic pain, abdominal swelling, constipation, and loss of appetite, among others. Common areas to which the cancer may spread include the lining of the abdomen, lymph nodes, lungs, and liver.

Psammoma body

A psammoma body is a round collection of calcium, seen microscopically. The term is derived from the Greek word ψάμμος (psámmos), meaning "sand".

Endometrioid tumor Medical condition

Endometrioid tumors are a class of tumor characterized by a resemblance to endometrium/ endometrial carcinoma, and over a third of cases have focal squamous differentiation.

Ovarian mucinous tumor

Mucinous tumors are part of the surface epithelial-stromal tumor group of ovarian neoplasms, and account for approximately 36% of all ovarian tumors. Approximately 75% are benign, 10% are borderline and 15% are malignant. Rarely, the tumor is seen bilaterally; approximately 5% of primary mucinous tumors are bilateral.

Surface epithelial-stromal tumor Medical condition

Surface epithelial-stromal tumors are a class of ovarian neoplasms that may be benign or malignant. Neoplasms in this group are thought to be derived from the ovarian surface epithelium or from ectopic endometrial or Fallopian tube (tubal) tissue. Tumors of this type are also called ovarian adenocarcinoma. This group of tumors accounts for 90% to 95% of all cases of ovarian cancer; however is mainly only found in postmenopausal women with the exception of the United States where 7% of cases occur in women under the age of 40. Serum CA-125 is often elevated but is only 50% accurate so it is not a useful tumor marker to assess the progress of treatment. 75% of women with epithelial ovarian cancer are found within the advanced-stages; however younger patients are more likely to have better prognoses than older patients.

Pancreatectomy

In medicine, a pancreatectomy is the surgical removal of all or part of the pancreas. Several types of pancreatectomy exist, including pancreaticoduodenectomy, distal pancreatectomy, segmental pancreatectomy, and total pancreatectomy. In recent years, the TP-IAT has also gained respectable traction within the medical community. These procedures are used in the management of several conditions involving the pancreas, such as benign pancreatic tumors, pancreatic cancer, and pancreatitis.

Pancreatic diseases are diseases that affect the pancreas, an organ in the human body located in the abdomen. The pancreas plays a role in the digestive and endocrine system, producing enzymes which aid the digestion process and the hormone insulin, which regulates blood sugar levels. The most common pancreatic disease is pancreatitis, an inflammation of the pancreas which could come in acute or chronic form. Other pancreatic diseases include Diabetes mellitus, Exocrine pancreatic insufficiency, Cystic fibrosis, Pseudocysts, Cysts, Congenital malformations, Neoplasms and Hemosuccus pancreaticus.

Acinic cell carcinoma Medical condition

Acinic cell carcinoma is a malignant tumor representing 2% of all salivary tumors. 90% of the time found in the parotid gland, 10% intraorally on buccal mucosa or palate. The disease presents as a slow growing mass, associated with pain or tenderness in 50% of the cases. Often appears pseudoencapsulated.

Cystadenocarcinoma Medical condition

Cystadenocarcinoma is a malignant form of a cystadenoma and is a cancer derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. Similar tumor histology has also been reported in the pancreas, although it is a considerably rarer entity representing 1 - 1.5% of all Pancreatic cancer.

The International Cancer Genome Consortium (ICGC) is a voluntary scientific organization that provides a forum for collaboration among the world's leading cancer and genomic researchers. The ICGC was launched in 2008 to coordinate large-scale cancer genome studies in tumours from 50 cancer types and/or subtypes that are of main importance across the globe.

Mucinous cystadenoma Medical condition

Mucinous cystadenoma is a benign cystic tumor lined by a mucinous epithelium. It is a type of cystic adenoma (cystadenoma).

Papillary serous cystadenocarcinoma Medical condition

Papillary serous cystadenocarcinomas are the most common form of malignant ovarian cancer making up 26 percent of ovarian tumours in women aged over 20 in the United States.

Intraductal papillary mucinous neoplasm Medical condition

Intraductal papillary mucinous neoplasm (IPMN) is a type of tumor that can occur within the cells of the pancreatic duct. IPMN tumors produce mucus, and this mucus can form pancreatic cysts. Although intraductal papillary mucinous neoplasms are benign tumors, they can progress to pancreatic cancer. As such IPMN is viewed as a precancerous condition. Once an intraductal papillary mucinous neoplasm has been found, the management options include close monitoring and pre-emptive surgery.

Mucinous cystadenocarcinoma of the lung (MCACL) is a very rare malignant mucus-producing neoplasm arising from the uncontrolled growth of transformed epithelial cells originating in lung tissue.

Pancreatic serous cystadenoma Medical condition

Pancreatic serous cystadenoma is a benign tumour of pancreas. It is usually found in the tail of the pancreas, and may be associated with von Hippel-Lindau syndrome.

Ovarian serous cystadenoma Medical condition

Ovarian serous cystadenoma, also known as serous cystadenoma, is the most common ovarian neoplasm, representing 20% of ovarian neoplasms, and is benign.

Solid pseudopapillary tumour Medical condition

A solid pseudopapillary tumour is a low-grade malignant neoplasm of the pancreas of papillary architecture that typically afflicts young women.

Cystic lesions of the pancreas Medical condition

Cystic lesions of the pancreas are a group of pancreatic lesions characterized by a cystic appearance. They can be benign or malignant.

Pancreatic mucinous cystic neoplasm (MCN) is a type of cystic lesion that occurs in the pancreas. Amongst individuals undergoing surgical resection of a pancreatic cyst, about 23 percent were mucinous cystic neoplasms. These lesions are benign, though there is a high rate of progression to cancer. As such, surgery should be pursued when feasible. The rate of malignancy present in MCN is about 10 percent. If resection is performed before invasive malignancy develops, prognosis is excellent. The extent of invasion is the single most important prognostic factor in predicting survival.

References

  1. 1 2 Kosary CL (2007). "Chapter 16: Cancers of the Ovary". In Ries LA, Young JL, Keel GE, Eisner MP, Lin YD, Horner MJ (eds.). SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics. SEER Program. Bethesda, MD: National Cancer Institute. pp. 133–144. Archived from the original on 2013-10-10.
  2. King JC, Ng TT, White SC, Cortina G, Reber HA, Hines OJ (October 2009). "Pancreatic serous cystadenocarcinoma: a case report and review of the literature". Journal of Gastrointestinal Surgery. 13 (10): 1864–1868. doi:10.1007/s11605-009-0926-3. PMID   19459016.
  3. Friebe V, Keck T, Mattern D, Schmitt-Graeff A, Werner M, Mikami Y, et al. (August 2005). "Serous cystadenocarcinoma of the pancreas: management of a rare entity". Pancreas. 31 (2): 182–187. doi:10.1097/01.mpa.0000167001.89018.3c. PMID   16025006.